KETAMINE FOR DEPRESSION

Ketamine targets the glutamate system — the brain's primary excitatory neurotransmitter — to trigger rapid formation of new neural connections. This process, known as synaptogenesis, restores synaptic density within hours of treatment.

Unlike traditional antidepressants that modulate serotonin and can take 4–6 weeks to show results, ketamine works through an entirely different mechanism. By blocking AMPA/NMDA receptors and subsequently increasing BDNF (brain-derived neurotrophic factor), it promotes neural plasticity and creates new pathways for healthier thought patterns.

For patients with treatment-resistant depression, this represents a breakthrough. When SSRIs, SNRIs, and other conventional therapies have not provided adequate relief, ketamine offers a scientifically validated alternative with rapid onset of action.

Clinical studies demonstrate that IV ketamine achieves a 72% response rate in patients with treatment-resistant depression — individuals who have not responded to two or more conventional antidepressant treatments. Many patients report significant improvement within hours to days of their first infusion, compared to the 4–6 week onset typical of traditional medications.